Institutional
Novo Holdings A/S
CIK 0001388325
$1.23B
Reported AUM
22
Positions
Q1 2026
Period
2026-05-15
Filed
The Brief · Novo Holdings A/S · Q1 2026
AI · grounded in 13F
Novo Holdings A/S exited its position in ZBIO, reducing its exposure by $52.6M. The fund also closed its position in INSM for $34.8M and established a new position in XENE worth $28.2M. Additionally, the fund trimmed its holdings in VALN by 54.1% and ASML by 16.7%.
Portfolio · Q1 2026
Top holdings
| # | Stock | Issuer | Price | Day % | 1Y Gr. | 5Y Gr. | Value | % of book | Δ shares (QoQ) | Status |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EWTX | EDGEWISE THERAPEUTICS INC | $39.75 | -1.49% | 181.97% | 154.73% | $168.5M | 13.65% | — | HELD |
| 2 | BN | BROOKFIELD CORP | $41.69 | -1.60% | -3.70% | 45.10% | $141.5M | 11.46% | — | HELD |
| 3 | ASML | ASML HOLDING N V | $1549.45 | -2.12% | 130.99% | 99.17% | $125.4M | 10.16% | — | HELD |
| 4 | MIRM | MIRUM PHARMACEUTICALS INC | $107.57 | -4.15% | 115.74% | 590.65% | $122.4M | 9.92% | — | HELD |
| 5 | MPLT | MAPLIGHT THERAPEUTICS INC | $15.02 | 22.01% | -27.25% | -9.68% | $74.9M | 6.07% | — | HELD |
| 6 | CRM | SALESFORCE INC | $188.46 | 3.83% | -23.90% | -27.44% | $73.4M | 5.95% | — | HELD |
| 7 | CRNX | CRINETICS PHARMACEUTICALS IN | $83.88 | 0.02% | 201.33% | 255.92% | $56.3M | 4.56% | — | HELD |
| 8 | ELVN | ENLIVEN THERAPEUTICS INC | $52.97 | -1.47% | 182.81% | 176.46% | $50.2M | 4.07% | — | HELD |
| 9 | PCVX | VAXCYTE INC | $52.98 | -2.97% | 65.35% | 108.16% | $50.0M | 4.05% | — | HELD |
| 10 | PHVS | PHARVARIS N V | $32.62 | -3.05% | 66.05% | 64.49% | $49.4M | 4.01% | — | HELD |
| 11 | AVBP | ARRIVENT BIOPHARMA INC | $30.04 | 0.20% | 60.99% | 39.46% | $44.8M | 3.63% | — | HELD |
| 12 | VRDN | VIRIDIAN THERAPEUTICS INC | $19.88 | 1.90% | 12.06% | 45.81% | $39.1M | 3.17% | — | HELD |
| 13 | CLDX | CELLDEX THERAPEUTICS INC NEW | $37.51 | 5.42% | 62.10% | -31.68% | $38.1M | 3.08% | — | HELD |
| 14 | APGE | APOGEE THERAPEUTICS INC | $134.20 | 0.02% | 255.42% | 484.87% | $37.9M | 3.07% | — | HELD |
| 15 | BMRN | BIOMARIN PHARMACEUTICAL INC | $61.37 | -1.13% | 6.76% | -26.29% | $37.3M | 3.02% | — | HELD |
| 16 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $9.61 | -2.44% | 49.69% | -68.54% | $34.0M | 2.75% | — | HELD |
| 17 | BABA | ALIBABA GROUP HLDG LTD | $115.00 | -0.17% | -0.70% | -26.70% | $32.3M | 2.62% | — | HELD |
| 18 | XENE | XENON PHARMACEUTICALS INC | $63.10 | -2.83% | 112.92% | 267.93% | $28.2M | 2.29% | — | HELD |
| 19 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $8.23 | -4.13% | -18.73% | -18.46% | $19.6M | 1.59% | — | HELD |
| 20 | VALN | VALNEVA SE | $5.07 | 0.20% | -29.76% | -90.43% | $6.6M | 0.54% | — | HELD |
| 21 | LNZA | LANZATECH GLOBAL INC | $5.40 | -0.92% | -87.73% | -99.44% | $2.5M | 0.21% | — | HELD |
| 22 | MQ | MARQETA INC | $18.36 | 1.60% | -17.00% | -84.19% | $1.8M | 0.15% | — | HELD |
Source: SEC EDGAR · accession 0001388325-26-000026. 13F discloses long positions only — shorts, foreign equities, and options are excluded.